Evaluation of protective effects of GnRH agonist or antagonist on ovarian reserve with anti-M?llerian hormone and histological analysis in a rat model using cisplatin

Basit Öğe Kaydı
dc.contributor.authorTas, Mustafa
dc.contributor.authorOner, Gokalp
dc.contributor.authorUlug, Pasa
dc.contributor.authorYavuz, Adem
dc.contributor.authorOzcelik, Bulent
dc.date.accessioned2024-11-07T13:35:01Z
dc.date.available2024-11-07T13:35:01Z
dc.date.issued2023
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractIntroduction: The aim of this prospective trial was to evaluate the ovarian reserve with anti-Mullerian hormone (AMH), which is the best predictor of ovarian reserve, and perform histological analysis after exposure to cisplatin with a GnRH agonist or antagonist.Material and methods: Twenty-four Wistar albino rats were randomly divided into three groups, each consisting of eight rats. In the GnRH agonist group (group 1), rats received a single dose of 50 mg/m2 cisplatin with 1 mg/kg triptorelin. In the GnRH antagonist group (group 2), rats received a single dose of 50 mg/m2 cisplatin with 1 mg/kg cetrorelix. In the control group (group 3), rats received 50 mg/m2 cisplatin. Ovarian reserve was assessed by AMH and histology.Results: Primary follicle counts were higher in group 2 (4.50 +/- 1.47 vs. 3.50 +/- 1.70 vs. 3.00 +/- 3.54) and secondary follicle counts were higher in group 1 (2.96 +/- 1.11 vs. 1.74 +/- 1.03 vs. 1.37 +/- 3.11). Numbers of tertiary follicles were higher both in groups 1 and 2 than the control group (1.36 +/- 0.83 vs. 0.84 +/- 0.99 vs. 0.50 +/- 0.75). The total follicle count of the study groups were signifi-cantly higher compared with the control group (14.32 +/- 5.96 vs. 12.48 +/- 4.12 vs. 10.63 +/- 6.80). AMH was significantly higher in groups 1 and 2 compared with the control group (18.56 +/- 25.33 vs. 16.48 +/- 24.66 vs. 9.37 +/- 26.54).Conclusions: This is the first prospective randomized controlled study show-ing the protective effects of GnRH agonist and antagonist on ovarian reserve after cisplatin exposure in an animal model.
dc.identifier.doi10.5114/aoms.2019.87540
dc.identifier.endpage451
dc.identifier.issn1734-1922
dc.identifier.issn1896-9151
dc.identifier.issue2
dc.identifier.pmid37034528
dc.identifier.scopus2-s2.0-85152171477
dc.identifier.scopusqualityQ2
dc.identifier.startpage448
dc.identifier.urihttps://doi.org/10.5114/aoms.2019.87540
dc.identifier.urihttps://hdl.handle.net/11480/16274
dc.identifier.volume19
dc.identifier.wosWOS:000980693500019
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTermedia Publishing House Ltd
dc.relation.ispartofArchives of Medical Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectovarian reserve
dc.subjectcisplatin
dc.subjectanti-M?llerian hormone
dc.titleEvaluation of protective effects of GnRH agonist or antagonist on ovarian reserve with anti-M?llerian hormone and histological analysis in a rat model using cisplatin
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu